[HTML][HTML] In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus

RN Esquivel, A Patel, SB Kudchodkar, DH Park… - Molecular Therapy, 2019 - cell.com
RN Esquivel, A Patel, SB Kudchodkar, DH Park, K Stettler, M Beltramello, JW Allen…
Molecular Therapy, 2019cell.com
Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high
risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an
approach that enables in vivo delivery of highly potent mAbs to control infections. We
engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the
ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels
persisting> 10 weeks in mice and> 3 weeks in non-human primate (NHPs), which is …
Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs), which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody, supporting the importance of this new platform.
cell.com